Member Biography

I am an early investigator with a research focus in understanding the tumor immune microenvironment to optimize outcomes with immune checkpoint blockade (ICB). Under the mentorship of Drs. Steven Reiner and Naiyer Rizvi, I conducted pre-clinical and translational research to understand the predictive capacity of self-renewing T cells and promote memory T cells using mTOR-PI3K-AKT inhibition. My current research is focused on clinical trial development based on my previous work. I plan to develop an investigator-initiated trial using combination ICB with PI3KD inhibition with a strong focus on correlative studies to evaluate the biologic mechanism. These studies would include analysis of PBMCs using TCR/ATAC-seq as well as tissue analysis via qmIF. I am also a sub-investigator on a trial evaluating a CD38 ADC in patients with squamous cell carcinoma and colorectal cancer. I plan to conduct correlative studies analyzing peripheral blood MDSC using flow cytometry. Under the mentorship of Dr. Patrick Loehrer, I plan to conduct translational and clinical research evaluating peripheral immune cells in thymic epithelial tumors with paraneoplastic syndromes to better understand potential combinatorial IRAE-directed therapies with ICB. We plan to analyze 40 patients with available blood to understand the differences in immune cell population in patients with paraneoplastic syndromes versus those without such syndromes.

Fellowship - Columbia University Irving Medical Center, New York, NY 2019-2022

Residency - Weill Cornell Medical Center, New York, NY 2016-2019

Pharm.D. - Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 2004-2010

M.D. - Indiana University School of Medicine, Indianapolis, IN 05/2016

Chief Fellow - Columbia University Irving Medical Center, New York, NY 01/2021-01/2022